Olema Pharmaceuticals, Inc. financial data

Symbol
OLMA on Nasdaq
Location
780 Brannan Street, San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.08K % -6.52%
Debt-to-equity 10.2 % +5.93%
Return On Equity -42.6 % +3.62%
Return On Assets -38.7 % +4.12%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68.6M shares +19.9%
Common Stock, Shares, Outstanding 68.6M shares +19.9%
Entity Public Float 454M USD +85.3%
Common Stock, Value, Issued 7K USD +75%
Weighted Average Number of Shares Outstanding, Basic 85.5M shares +51.9%
Weighted Average Number of Shares Outstanding, Diluted 85.5M shares +51.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 140M USD +34.3%
General and Administrative Expense 17.1M USD -1.36%
Operating Income (Loss) -157M USD -29.2%
Nonoperating Income (Expense) 14.8M USD +23.6%
Net Income (Loss) Attributable to Parent -142M USD -29.8%
Earnings Per Share, Basic -1 USD/shares +3.9%
Earnings Per Share, Diluted -1 USD/shares +3.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 52.5M USD +211%
Marketable Securities, Current 309M USD +39.3%
Cash, Cash Equivalents, and Short-term Investments 362M USD +51.4%
Assets, Current 368M USD +51.8%
Property, Plant and Equipment, Net 560K USD -40.7%
Operating Lease, Right-of-Use Asset 1.69M USD -7.11%
Other Assets, Noncurrent 15K USD -6.25%
Assets 382M USD +50.1%
Accounts Payable, Current 934K USD -78.5%
Employee-related Liabilities, Current 621K USD +56.8%
Liabilities, Current 33.2M USD +25%
Operating Lease, Liability, Noncurrent 602K USD -29.9%
Liabilities 36.8M USD +34.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 314K USD
Retained Earnings (Accumulated Deficit) -509M USD -38.8%
Stockholders' Equity Attributable to Parent 345M USD +52%
Liabilities and Equity 382M USD +50.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -44M USD -87.2%
Net Cash Provided by (Used in) Financing Activities 222K USD -97.5%
Net Cash Provided by (Used in) Investing Activities -45.1M USD -124%
Common Stock, Shares Authorized 490M shares 0%
Common Stock, Shares, Issued 68.6M shares +19.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -88.8M USD -155%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 52.5M USD +211%
Deferred Tax Assets, Valuation Allowance 105M USD +46%
Deferred Tax Assets, Gross 105M USD +44.9%
Operating Lease, Liability 1.76M USD -10.6%
Payments to Acquire Property, Plant, and Equipment 153K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -142M USD -29.9%
Lessee, Operating Lease, Liability, to be Paid 1.87M USD -11.9%
Property, Plant and Equipment, Gross 1.75M USD -7.1%
Operating Lease, Liability, Current 1.15M USD +4.53%
Lessee, Operating Lease, Liability, to be Paid, Year Two 69K USD -73.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.17M USD -5.94%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 110K USD -29.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 263K USD -68%
Deferred Tax Assets, Operating Loss Carryforwards 60.6M USD +35.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 1.23M USD +8.67%
Additional Paid in Capital 854M USD +43.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 128K USD +45.5%
Share-based Payment Arrangement, Expense 21M USD +10.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%